Sanofi India Board Approves FY25 Audited Results, Recommends Final Dividend of ₹48/Share
Sanofi India's Board approved audited FY25 results, recommending a final dividend of ₹48 per share, bringing the total to ₹123. Key appointments include Mrs. Rajani Kesari as Independent Director (effective April 1, 2026) and Ms. Sudipta Chakraborty as Whole-time Director (effective March 1, 2026). Mr. Rodolfo Hrosz resigned as Non-Executive Director.
The dividend recommendation and key management appointments are significant for stakeholders, impacting investor confidence and corporate governance. The financial results are steady.
The company reported positive financial results, recommended a substantial final dividend, and made key appointments, indicating stability and forward-looking management.
Sanofi India Limited announced the outcome of its Board Meeting held on February 25, 2026. The Board considered and approved the Audited Financial Results for the Quarter and Financial Year ended December 31, 2025. The company reported an unmodified audit opinion from its statutory auditors, M/s Price Waterhouse & Co. Chartered Accountants LLP.
The Board recommended a final dividend of ₹48 per equity share, with a face value of ₹10 each, for the Financial Year ended December 31, 2025. This is in addition to the interim dividend of ₹75 per equity share declared on October 29, 2025, bringing the total dividend for 2025 to ₹123 per equity share. The final dividend is subject to shareholder approval at the upcoming 70th Annual General Meeting.
Furthermore, the Board approved significant changes in directorships. Mrs. Rajani Kesari has been appointed as an Additional Director and Independent Director for a term of five years, effective April 1, 2026, subject to shareholder approval. Mr. Rodolfo Hrosz resigned as Non-Executive Director, effective February 28, 2026, due to other commitments. Ms. Sudipta Chakraborty has been appointed as an Additional Director and Whole-time Director for a term of three years, effective March 1, 2026, and will also be designated as Key Managerial Personnel and Senior Management Personnel.
The financial results for the year ended December 31, 2025, show Total Income of ₹18,571 crore and Profit Before Tax of ₹4,447 crore from continuing operations. For the quarter ended December 31, 2025, Total Income was ₹4,226 crore and Profit Before Tax was ₹830 crore. The company's total equity stands at ₹7,492 crore as of December 31, 2025.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.